Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 1.28 ($0.02) and last traded at GBX 1.30 ($0.02), with a volume of 3551609 shares trading hands. The stock had previously closed at GBX 1.33 ($0.02).
Hemogenyx Pharmaceuticals Stock Performance
The company has a market capitalization of £17.55 million, a PE ratio of -131.00 and a beta of 3.05. The company has a debt-to-equity ratio of 105.93, a quick ratio of 6.72 and a current ratio of 3.33. The stock’s fifty day simple moving average is GBX 1.50 and its 200-day simple moving average is GBX 2.05.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Stories
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Market Cap Calculator: How to Calculate Market Cap
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
